Experienced in Acute Erythroid Leukemia (AEL)

Dr. Dennis J. Meisner

Hematology Oncology | Hematology | Oncology
3204 Johnson Rd, Suite 10, 
Steubenville, OH 
Experienced in Acute Erythroid Leukemia (AEL)
3204 Johnson Rd, Suite 10, 
Steubenville, OH 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Dennis Meisner is a Hematologist Oncology specialist and a Hematologist in Steubenville, Ohio. Dr. Meisner is rated as an Experienced provider by MediFind in the treatment of Acute Erythroid Leukemia (AEL). His top areas of expertise are Small Cell Lung Cancer (SCLC), Colorectal Cancer, Inflammatory Breast Cancer, and Pleuropulmonary Blastoma.

His clinical research consists of participating in 8 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology Oncology
Hematology
Oncology
Licenses
Internal Medicine in PA
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Cigna
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
UPMC
  • EPO
  • PPO

Locations

3204 Johnson Rd, Suite 10, Steubenville, OH 43952

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) After Neoadjuvant Chemotherapy
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) After Neoadjuvant Chemotherapy
Enrollment Status: Active_not_recruiting
Publish Date: October 09, 2025
Intervention Type: Other, Radiation, Procedure, Biological
Study Drug: Pembrolizumab
Study Phase: Phase 3
Phase II Randomized Placebo-Controlled Trial of Cisplatin With or Without ABT-888 (Veliparib) in Metastatic Triple-Negative Breast Cancer and/or BRCA Mutation-Associated Breast Cancer, With or Without Brain Metastases
Phase II Randomized Placebo-Controlled Trial of Cisplatin With or Without ABT-888 (Veliparib) in Metastatic Triple-Negative Breast Cancer and/or BRCA Mutation-Associated Breast Cancer, With or Without Brain Metastases
Enrollment Status: Completed
Publish Date: May 16, 2025
Intervention Type: Other, Drug
Study Drugs: Cisplatin, Veliparib
Study Phase: Phase 2
A Randomized, Phase II Efficacy Assessment of Multiple MET Kinase Inhibitors (Cabozantinib [NSC #761968], Crizotinib [NSC #749005], Savolitinib [NSC #785348], and Sunitinib [NSC #736511]) in Metastatic Papillary Renal Carcinoma (PAPMET)
A Randomized, Phase II Efficacy Assessment of Multiple MET Kinase Inhibitors (Cabozantinib [NSC #761968], Crizotinib [NSC #749005], Savolitinib [NSC #785348], and Sunitinib [NSC #736511]) in Metastatic Papillary Renal Carcinoma (PAPMET)
Enrollment Status: Completed
Publish Date: January 13, 2025
Intervention Type: Procedure, Drug
Study Drugs: Cabozantinib S-Malate, Crizotinib, Savolitinib, Sunitinib Malate
Study Phase: Phase 2
Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer
Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: January 13, 2025
Intervention Type: Other
Study Phase: Phase 3
Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients With High-Risk, Hormone Receptor-Positive and HER2/Neu Negative Breast Cancer
Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients With High-Risk, Hormone Receptor-Positive and HER2/Neu Negative Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: December 27, 2024
Intervention Type: Drug, Other
Study Drugs: Anastrozole, Everolimus, Exemestane, Goserelin Acetate, Letrozole, Leuprolide Acetate, Tamoxifen Citrate
Study Phase: Phase 3
A Randomized Phase III Post-operative Trial of Platinum Based Chemotherapy vs. Capecitabine in Patients With Residual Triple-Negative Basal-Like Breast Cancer Following Neoadjuvant Chemotherapy
A Randomized Phase III Post-operative Trial of Platinum Based Chemotherapy vs. Capecitabine in Patients With Residual Triple-Negative Basal-Like Breast Cancer Following Neoadjuvant Chemotherapy
Enrollment Status: Active_not_recruiting
Publish Date: July 03, 2024
Intervention Type: Drug
Study Drugs: Capecitabine, Carboplatin, Cisplatin
Study Phase: Phase 3
A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for HER2 Negative Breast Cancer: The ABC Trial
A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for HER2 Negative Breast Cancer: The ABC Trial
Enrollment Status: Terminated
Publish Date: April 05, 2023
Intervention Type: Other, Drug
Study Drug: Aspirin
Study Phase: Phase 3
A Phase II Study of Talazoparib (BMN 673) in Patients With Homologous Recombination Repair Deficiency Positive Stage IV Squamous Cell Lung Cancer (Lung-Map Sub-Study)
A Phase II Study of Talazoparib (BMN 673) in Patients With Homologous Recombination Repair Deficiency Positive Stage IV Squamous Cell Lung Cancer (Lung-Map Sub-Study)
Enrollment Status: Completed
Publish Date: June 23, 2021
Intervention Type: Other, Drug
Study Drug: Talazoparib
Study Phase: Phase 2
View 7 Less Clinical Trials
Similar Doctors
Advanced in Acute Erythroid Leukemia (AEL)
Dr. Ashkan Emadi
Hematology Oncology | Hematology | Oncology
Advanced in Acute Erythroid Leukemia (AEL)
Dr. Ashkan Emadi
Hematology Oncology | Hematology | Oncology

West Virginia University Medical Corporation

1 Medical Ctr Dr, 
Morgantown, WV 
 (61.8 miles away)
304-293-4500
Languages Spoken:
English, Farsi
See accepted insurances
Accepting New Patients

Ashkan Emadi is a Hematologist Oncology specialist and a Hematologist in Morgantown, West Virginia. Dr. Emadi is rated as a Distinguished provider by MediFind in the treatment of Acute Erythroid Leukemia (AEL). His top areas of expertise are Acute Myeloid Leukemia (AML), Acute Promyelocytic Leukemia, Leukemia, Bone Marrow Aspiration, and Bone Marrow Transplant. Dr. Emadi is currently accepting new patients.

Experienced in Acute Erythroid Leukemia (AEL)
Dr. Ranga S. Brahmamdam
Hematology Oncology | Hematology | Oncology
Experienced in Acute Erythroid Leukemia (AEL)
Dr. Ranga S. Brahmamdam
Hematology Oncology | Hematology | Oncology

Sch Professional Corporation

750 E Park Ave, 
Columbiana, OH 
 (35.9 miles away)
330-892-0442
Languages Spoken:
English, Hindi, Telugu
See accepted insurances
Accepting New Patients

Ranga Brahmamdam is a Hematologist Oncology specialist and a Hematologist in Columbiana, Ohio. Dr. Brahmamdam is rated as an Advanced provider by MediFind in the treatment of Acute Erythroid Leukemia (AEL). His top areas of expertise are Non-Hodgkin Lymphoma, Thrombotic Thrombocytopenic Purpura, Burkitt Lymphoma, Large-Cell Immunoblastic Lymphoma, and Bone Marrow Aspiration. Dr. Brahmamdam is currently accepting new patients.

Annie Im
Experienced in Acute Erythroid Leukemia (AEL)
Dr. Annie Im
Hematology Oncology
Experienced in Acute Erythroid Leukemia (AEL)
Dr. Annie Im
Hematology Oncology

UPMC Hillman Cancer Center

5115 Centre Avenue, Hillman Cancer Center, 
Pittsburgh, PA 
 (38.7 miles away)
412-695-5772
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Annie Im, MD, is an Associate Professor of Medicine at the University of Pittsburgh School of Medicine, and a hematologist/medical oncologist specializing and conducting research in hematologic malignancies (such as acute leukemia), drug development, stem cell transplantation, and graft-versus-host-disease. In addition, Dr. Im leads the chronic graft-versus-host-disease and stem cell transplant survivorship clinic. Dr. Im is rated as a Distinguished provider by MediFind in the treatment of Acute Erythroid Leukemia (AEL). Her top areas of expertise are Acute Myeloid Leukemia (AML), Chronic Graft Versus Host Disease (cGvHD), Graft Versus Host Disease (GvHD), Bone Marrow Aspiration, and Bone Marrow Transplant.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Meisner's expertise for a condition
ConditionClose
    View All 33 Advanced Conditions
    View All 104 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile